Three million people don't know they have TB because the tools to find them don't exist where they live.
Tuberculosis remains one of humanity's oldest and most persistent adversaries, killing more than a million people each year while millions more carry the disease unknowingly, untested, and untreated. In seven of the world's highest-burden countries, researchers have now validated a portable, battery-operated diagnostic device — MiniDock MTB — that returns results in under half an hour with accuracy that surpasses long-standing standard methods. The tool asks a quiet but consequential question: what becomes possible when the means of knowing arrives where the suffering already is?
- Three million people worldwide are unknowingly infected with TB, coughing and spreading a disease that kills over a million annually — largely because diagnostic tools never reach them.
- MiniDock MTB, tested across 1,380 participants in Nigeria, India, South Africa, the Philippines, Vietnam, Zambia, and Uganda, detected TB in 12 to 25 minutes with 86% sensitivity and 98% specificity using sputum samples.
- The device outperformed traditional smear microscopy by 24 percentage points and met WHO benchmarks for decentralized testing — a meaningful threshold in the push to bring diagnosis to clinics without laboratory infrastructure.
- Healthcare workers across India and South Africa rated the device highly in usability trials, with 94% calling it acceptable and noting it required minimal training to operate.
- Despite promising results, real-world deployment and integration with drug-resistance testing remain unevaluated, leaving the distance between a successful trial and a transformed health system still to be crossed.
Tuberculosis kills more than a million people every year, yet roughly three million of those infected — a quarter of adults and half of children worldwide — never know they carry it. They cough, they spread the disease, and they go untreated, not because treatment doesn't exist, but because the tools to find them don't reach where they live. A new portable device may begin to change that calculus.
Researchers across seven high-burden countries — Nigeria, India, South Africa, the Philippines, Vietnam, Zambia, and Uganda — enrolled 1,380 participants between September 2024 and March 2025 to test MiniDock MTB, a battery-operated diagnostic platform developed by Guangzhou Pluslife Biotech. The device was designed for settings where laboratory infrastructure is thin and the nearest PCR machine may be hours away. Participants were at least 12 years old and suspected of active TB based on persistent cough, abnormal chest X-rays, or elevated inflammatory markers.
The results were striking. Using sputum samples, MiniDock MTB achieved 86% sensitivity and 98% specificity — catching most cases while almost never raising false alarms. Tongue swabs performed slightly lower at 80% sensitivity but remained highly specific. Combined, both sample types pushed sensitivity to 88%. The device outperformed traditional smear microscopy by 24 percentage points and met WHO benchmarks for decentralized testing, all within 12 to 25 minutes.
The study population reflected the real communities this tool would serve: 19% were living with HIV, 14% had diabetes, and TB prevalence ranged from 4.8% in India to 28% in Nigeria. When healthcare workers in India and South Africa used the device in simulated clinical sessions, 94% called it acceptable, praising its ease of use and minimal training requirements.
Still, a successful trial is not the same as a transformed system. Researchers acknowledge that real-world deployment across clinics in TB-endemic countries remains unstudied, as does the critical question of integrating drug-resistance testing. Those answers will determine whether MiniDock MTB closes the gap between the millions who have tuberculosis and the millions who do not yet know it.
Tuberculosis kills more than a million people every year, yet roughly three million of them—a quarter of infected adults and half of infected children worldwide—don't know they have it. They cough, they spread the disease, and they never get treated, because the tools to find them don't exist where they live. A new portable device may begin to change that.
Researchers working across seven countries with the heaviest TB burdens—Nigeria, India, South Africa, the Philippines, Vietnam, Zambia, and Uganda—tested a battery-operated diagnostic platform called MiniDock MTB. The device, developed by Guangzhou Pluslife Biotech, is designed to work in places where laboratory infrastructure is thin, where trained technicians are scarce, and where a patient's cough might never be confirmed as tuberculosis because the nearest PCR machine is hours away.
The study enrolled 1,380 people between September 2024 and March 2025, all of them at least 12 years old and suspected of having active TB—they had persistent coughs lasting two weeks or longer, or they showed risk factors like abnormal chest X-rays or elevated inflammatory markers. Researchers collected sputum samples and tongue swabs from each participant, then ran them through the MiniDock MTB and compared the results against the gold standard: smear microscopy and Xpert MTB/RIF Ultra, a molecular test that requires more sophisticated equipment.
The numbers were striking. Using sputum samples, the device detected TB with 86% sensitivity and 98% specificity—meaning it caught most cases and almost never gave false alarms. Tongue swabs were slightly less sensitive at 80%, but still highly specific. When researchers combined both sample types, sensitivity climbed to 88%. The device outperformed traditional smear microscopy by 24 percentage points for sputum and 18 points for tongue swabs, meeting the World Health Organization's benchmarks for decentralized testing. Results came back in 12 to 25 minutes.
The study population reflected the real world where this tool would be deployed. Nineteen percent were living with HIV, a group that historically presents diagnostic challenges because their TB often comes with lower bacterial loads. Sixteen percent had culture-verified TB. Fourteen percent had diabetes. TB prevalence varied dramatically across sites—from 4.8% in India to 28% in Nigeria, with African sites showing higher bacterial loads than Asian ones. The median age was 41 years, and 44% were women.
When healthcare workers—clinicians, nurses, laboratory staff—actually used the device in simulated sessions at facilities in India and South Africa, they rated it highly. The median usability score was 75 out of 100. Ninety-four percent called it acceptable. They said it was easy to operate, required minimal training, and made sense for resource-limited settings. No adverse events were reported, and repeating tests offered no additional benefit.
Yet the path from a successful trial to widespread use remains uncertain. The device works. It's fast, it's accurate, it's portable, and healthcare workers like it. But researchers acknowledge that real-world implementation—the messy business of actually deploying it across clinics and health posts in countries where TB is endemic—still needs to be studied. So does integrating drug-resistance testing, which is critical because some TB strains no longer respond to standard antibiotics. Those questions will shape whether MiniDock MTB becomes a tool that closes the gap between the millions who have TB and the millions who don't yet know it.
Citas Notables
The device is easy to operate and appropriate in resource-limited settings, even with limited training, given its compatibility with non-invasive sampling.— Healthcare workers in the usability assessment
La Conversación del Hearth Otra perspectiva de la historia
Why does it matter that this test works with tongue swabs instead of just sputum?
Because sputum is hard to collect. You have to cough it up, and some people can't produce enough, especially if they're very sick or very young. A tongue swab is non-invasive. You just brush the back of the throat. That opens the door to testing people who would otherwise slip through.
The study mentions lower sensitivity in women and people with HIV. Why is that a problem?
Those groups often have what's called paucibacillary disease—fewer bacteria in their samples. It's a known diagnostic challenge across all TB tests, not just this one. But it means the device catches 80% of cases in those populations, not 86%. That gap matters when you're trying to find every person with TB.
What's the difference between this and the Xpert test they compared it against?
Xpert MTB/RIF Ultra is the current gold standard, but it requires electricity, a stable power supply, and trained lab technicians. It's centralized. MiniDock is battery-operated and designed for clinics and health posts. You don't need a laboratory. That's the whole point.
The study says drug-resistance testing still needs work. How urgent is that?
Very. If you diagnose someone with TB but can't tell whether their strain is drug-resistant, you might start them on standard treatment that won't work. That wastes time and breeds more resistance. The device detects TB, but it doesn't yet tell you which drugs will kill it.
Why did TB prevalence vary so much—from 4.8% in India to 28% in Nigeria?
Different countries have different disease burdens and different populations in the study. Nigeria's sites may have enrolled sicker people, or the TB burden there is simply higher. The point is the device worked across all of them, in different epidemiological contexts.
If 94% of healthcare workers found it acceptable, what's holding back deployment?
Proof of concept in a trial is different from rolling it out across a country. You need supply chains, training programs, quality assurance, integration with existing TB programs. You need to know it works when it's not being watched by researchers. That's the next phase.